HBOT for Radiation Injury: What the Evidence Supports

The short answer: Delayed radiation injury, meaning osteoradionecrosis of bone and soft tissue radionecrosis, is one of the few hyperbaric indications where all three US authorities agree. The FDA has cleared chambers for radiation injury, the UHMS lists it as approved indication #11, and Medicare covers both forms under NCD 20.29. The 2023 Cochrane review of 18 randomized trials with 1,071 participants found HBOT may improve outcomes for late radiation injury of the head, neck, bladder, and rectum, at low-to-moderate certainty, with no effect on short-term survival. Treatment runs at 2.0–2.4 ATA for about 90 minutes per session, typically 20–40 sessions, in physician-supervised clinical settings.

Radiotherapy saves lives, and roughly half of the people who receive it become long-term survivors, as the Cochrane review notes. A fraction of those survivors develop late radiation tissue injury months or years after treatment ends: tissue that slowly loses its blood supply until bone or soft tissue breaks down. The jawbone after head and neck radiotherapy is the classic site, and a routine dental extraction in an irradiated mandible is the classic trigger. The bladder and rectum after pelvic radiotherapy are the other major sites.

This is also the rare corner of hyperbaric medicine where the regulatory lists do not argue with each other. Our hub guide to what HBOT is actually FDA-cleared to treat shows how often the FDA, UHMS, and Medicare lists diverge: burns and severe anemia are cleared and approved, yet Medicare refuses to pay for either. Delayed radiation injury is the opposite case. All three lists carry it, in nearly the same words.

Disclosure: Superhuman Chambers manufactures and sells hyperbaric chambers for wellness operators and home use. This article summarizes published clinical evidence and regulatory information for education only and is not medical advice. Operators are responsible for the claims, protocols, referral decisions, and compliance obligations in their own jurisdiction.

What delayed radiation injury actually is

Radiation injures normal tissue progressively. The model that shaped the field, published by Robert Marx in 1983, describes irradiated tissue as hypocellular, hypovascular, and hypoxic: fewer cells, fewer blood vessels, and chronically low oxygen. In that environment, even minor trauma such as a tooth extraction can overwhelm the tissue’s capacity to heal.

Two named conditions fall under the indication:

• Osteoradionecrosis (ORN) is exposed, non-healing bone in an irradiated field, most often the mandible after head and neck cancer treatment. It can appear spontaneously, but it is frequently precipitated by dental extractions or implant placement in irradiated bone.
• Soft tissue radionecrosis covers the same process in non-bony tissue: the bladder wall (radiation cystitis), the rectum (radiation proctitis), the chest wall, and the skin and mucosa of the head and neck.

The logic of HBOT here is mechanistic rather than speculative. Breathing 100% oxygen at 2.0 ATA and above steeply raises dissolved plasma oxygen, and repeated exposure stimulates new capillary growth in irradiated tissue. Marx’s animal work in 1990 tied the angiogenic response directly to the oxygen dose, which is why this indication has always lived at clinical pressures rather than mild ones.

One indication where all three lists agree

The three US lists are laid out in full in the FDA-cleared indications guide, but this row is worth isolating.

Two details in the Medicare wording matter. First, Medicare splits the indication into two separately covered conditions, bone and soft tissue. Second, both are covered “as an adjunct to conventional treatment,” which is an accurate summary of how the therapy is actually used: HBOT accompanies surgery, dental care, antibiotics, and wound management; it does not replace them.

What the clinical evidence shows

The evidence base is real, randomized, and genuinely mixed. It separates into three questions: preventing ORN around dental surgery, treating established ORN, and treating pelvic soft tissue injury.

Prevention: the Marx trial and its modern challenge

The founding study is Marx, Johnson, and Kline’s 1985 randomized trial in the Journal of the American Dental Association. Seventy-four patients who needed teeth removed from irradiated mandibles were randomized to hyperbaric oxygen or to penicillin. ORN developed in 5.4% of the HBOT group versus 29.9% of the antibiotic group (p = 0.005). The trial used 20 dives before extraction and 10 after at 2.4 ATA for 90 minutes, and it established the prophylactic practice that became the widely taught Marx 30/10 protocol: 30 sessions before surgery on irradiated bone, 10 after.

The modern test of that practice is HOPON (Shaw et al., 2019), a UK phase 3 randomized trial of 144 patients needing extractions or implants in mandibles irradiated above 50 Gy. The HBOT arm received 30 dives at 2.4 ATA. ORN rates came back low and nearly identical: 6.4% with HBOT versus 5.7% without. The HBOT group did report fewer acute symptoms, but the authors concluded that with modern radiotherapy and dental care, baseline ORN risk has fallen enough that routine prophylaxis around dental surgery is no longer justified. It remains only the second randomized trial in this setting, and its low event rate limits how far the conclusion generalizes.

Established ORN: one negative trial, one inconclusive one

For bone that has already broken down, the randomized record is thinner and less comfortable. The ORN96 trial (Annane et al., 2004), a double-blind, placebo-controlled study across 12 French university hospitals using the 30-plus-10 protocol at 2.4 ATA, was stopped early for potentially worse outcomes in the HBOT arm: one-year recovery was 19% with HBOT versus 32% with placebo, a difference that was not statistically significant but that the field has debated ever since. Forner et al. (2022), combining the DAHANCA-21 and NWHHT2009-1 randomized trials, found healing of mandibular ORN in 70% with HBOT versus 51% with standard care after removal of necrotic bone: a trend favoring HBOT that did not reach significance in a small sample.

Pelvic radiation injury: the strongest modern signals

Soft tissue injury in the pelvis now carries some of the most persuasive randomized data in the field. Clarke et al. (2008) ran a randomized, double-blind, sham-controlled crossover trial for chronic refractory radiation proctitis and found significantly improved healing scores with HBOT, maintained at long-term follow-up. RICH-ART (Oscarsson et al., Lancet Oncology 2019) randomized 79 patients with late radiation cystitis to 30–40 sessions at 2.4–2.5 ATA or standard care: urinary symptom scores improved by 17.8 points with HBOT versus 7.7 with standard care, a significant 10.1-point gap (p = 0.013).

Evidence snapshot

Does hyperbaric oxygen promote cancer recurrence?

This is the question every oncology-adjacent reader asks, and it has a direct answer in the literature. A 2003 systematic review by Feldmeier examined clinical, animal, and cell-culture evidence and concluded that published data provide little basis for HBOT enhancing malignant growth or metastasis, and that a history of malignancy is not a contraindication to treatment. The 2023 Cochrane review found no effect of HBOT on death at one year (RR 0.93, 95% CI 0.47–1.83), which is consistent with that picture. These patients are cancer survivors being treated for a complication of their cure, and the evidence supports treating them without fear of feeding the disease.

How treatment is actually dosed

The protocols across this literature are remarkably consistent: 2.0–2.4 ATA, 80–90 minutes of 100% oxygen breathing, once daily, five days per week. Course length runs from 20 sessions in older prophylaxis trials to 30–40 sessions for established injury. The Marx staging system escalates further for refractory ORN: patients begin with 30 dives, responders continue to 40, and non-responders advance to surgical stages with additional dives before and after resection.

The pressure point deserves emphasis. Every trial cited above ran at 2.0 ATA or higher on hard-shell clinical equipment, which our guide to hyperbaric chamber pressure levels covers in detail. Nothing in this evidence base was generated at 1.3 ATA.

Limitations of the evidence

Start with what is supported: regulatory clearance, medical-society approval, and Medicare coverage all align here, and the 2023 Cochrane review finds HBOT is probably helpful for late radiation injury of the head, neck, bladder, and rectum, with moderate-certainty evidence for pain reduction in ORN and low-certainty evidence for overall resolution.

The honest caveats follow. The trials are small: 18 randomized studies spread across nearly four decades and five anatomical sites add up to barely a thousand participants. The certainty ratings are low to moderate throughout. The strongest historical claim, routine ORN prevention around dental extractions, was not reproduced in the modern HOPON trial, and the only double-blind trial of established mandibular ORN was stopped for a possible harm signal that has never been fully explained. HBOT also carries real, mostly minor adverse effects in this literature: temporary reductions in visual acuity and ear barotrauma on compression. And every positive finding was generated at 2.0 ATA and above, on hard-shell clinical equipment under medical supervision: exactly the operating range of clinical-grade hard-shells, and exactly the setting this indication demands.

What this means for wellness operators

This is a cancer-care-adjacent indication, and it asks more of an operator than most.

Claims discipline first. Medicare’s phrasing is the model: adjunct to conventional treatment. Delayed radiation injury is a legitimate, covered, physician-managed use of HBOT, and that fact can be stated accurately in educational content. It cannot be turned into a marketing claim that a wellness chamber treats osteoradionecrosis or radiation cystitis. The audience searching these terms includes head and neck cancer survivors facing jaw surgery; content written for them has to be precise, sourced, and free of promises.

Referral, not in-house delivery. Treatment for ORN and soft tissue radionecrosis happens in hospital-affiliated wound care and hyperbaric departments, under hyperbaric physicians, coordinated with oral surgeons and oncologists, and billed through Medicare and commercial insurance. A wellness operator’s credible role is understanding the indication well enough to recognize it and refer it. Our wound healing evidence guide makes the same distinction for diabetic ulcers: medical wound care is physician-supervised, and that boundary is a trust asset rather than a limitation.

Equipment class is part of the story. The entire radiation-injury literature ran at 2.0 ATA and above on hard-shell systems. Operators evaluating equipment for a serious, evidence-anchored program will want to weight that capability heavily: a clinical-grade hard-shell like the Superhuman L1 operates in the pressure class the published protocols actually used, which the hard-shell versus soft-shell comparison breaks down by engineering and indication. Speaking accurately about this evidence is one of the ways a premium operator demonstrates they understand the difference between wellness positioning and clinical medicine.

References

1. Lin ZC, Bennett MH, Hawkins GC, Azzopardi CP, Feldmeier J, Smee R, Milross C. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database of Systematic Reviews 2023, Issue 8, Art. No. CD005005. DOI: 10.1002/14651858.CD005005.pub5.
2. Marx RE, Johnson RP, Kline SN. Prevention of osteoradionecrosis: a randomized prospective clinical trial of hyperbaric oxygen versus penicillin. Journal of the American Dental Association 1985;111(1):49-54. PMID: 3897335.
3. Shaw RJ, Butterworth CJ, Silcocks P, et al. HOPON (Hyperbaric Oxygen for the Prevention of Osteoradionecrosis): a randomized controlled trial of hyperbaric oxygen to prevent osteoradionecrosis of the irradiated mandible after dentoalveolar surgery. International Journal of Radiation Oncology, Biology, Physics 2019;104(3):530-539. PMID: 30851351.
4. Annane D, Depondt J, Aubert P, et al. Hyperbaric oxygen therapy for radionecrosis of the jaw: a randomized, placebo-controlled, double-blind trial from the ORN96 study group. Journal of Clinical Oncology 2004;22(24):4893-4900. PMID: 15520052.
5. Forner LE, Dieleman FJ, Shaw RJ, et al. Hyperbaric oxygen treatment of mandibular osteoradionecrosis: combined data from the two randomized clinical trials DAHANCA-21 and NWHHT2009-1. Radiotherapy and Oncology 2022;166:137-144. DOI: 10.1016/j.radonc.2021.11.021.
6. Clarke RE, Tenorio LMC, Hussey JR, et al. Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up. International Journal of Radiation Oncology, Biology, Physics 2008;72(1):134-143. PMID: 18342453.
7. Oscarsson N, Müller B, Rosén A, et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2-3 trial. Lancet Oncology 2019;20(11):1602-1614. DOI: 10.1016/S1470-2045(19)30494-2.
8. Huang ET, ed. UHMS Hyperbaric Medicine Indications Manual. 15th ed. North Palm Beach, FL: Best Publishing Company; 2023. Indication 11: Delayed radiation injury (soft tissue and bony necrosis). ISBN 978-1-947239-42-5.
9. Centers for Medicare & Medicaid Services. National Coverage Determination 20.29: Hyperbaric Oxygen Therapy. Medicare NCD Manual Pub. 100-03, Ch. 1 Part 1. Version 4, effective 3 April 2017. Covered conditions 11 and 12: osteoradionecrosis and soft tissue radionecrosis as adjuncts to conventional treatment.